CLINICAL TRIAL: RALTEGRAVIR (MK-0518), ON THE LEVEL OF PERSISTENT PLASMA VIREMIA

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：通过一项检测极少量病毒的试验，了解添加雷特格韦是否能降低血液中的HIV含量。 研究对象：50名HIV-1感染者。 程序（方法）：A5244为双盲、随机、安慰剂对照研究。在研究入组时，受试者将被随机分配至以下组之一：A组（立即 强化）或B组（延迟强化）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: To find out if adding raltegravir reduces the amount of HIV in the blood using a test that measures very low amounts of the virus. Participants: 50 HIV-1 infected men and women. Procedures (methods): A5244 is double-blind, randomized, placebo-controlled study. At study entry the subjects will be randomized to one of the following arms: Arm A (immediate intensification) or Arm B (delayed intensification).